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Apolipoprotein J is a hepatokine regulating muscle
glucose metabolism and insulin sensitivity
Ji A Seo 1,2,17, Min-Cheol Kang 1,3,17, Won-Mo Yang1,4,17, Won Min Hwang 1,5, Sang Soo Kim 1,6,
Soo Hyun Hong1,11, Jee-In Heo 2, Achana Vijyakumar1, Leandro Pereira de Moura 1,12, Aykut Uner 1,
Hu Huang 1,13, Seung Hwan Lee 1,14, Inês S. Lima1,15, Kyong Soo Park 4, Min Seon Kim 7, Yossi Dagon1,
Thomas E. Willnow 8, Vanita Aroda9,10,16, Theodore P. Ciaraldi 9,10, Robert R. Henry9,10,18 &
Young-Bum Kim 1✉
Crosstalk between liver and skeletal muscle is vital for glucose homeostasis. Hepatokines,
liver-derived proteins that play an important role in regulating muscle metabolism, are
important to this communication. Here we identify apolipoprotein J (ApoJ) as a novel
hepatokine targeting muscle glucose metabolism and insulin sensitivity through a low-density
lipoprotein receptor-related protein-2 (LRP2)-dependent mechanism, coupled with the insulin
receptor (IR) signaling cascade. In muscle, LRP2 is necessary for insulin-dependent IR
internalization, an initial trigger for insulin signaling, that is crucial in regulating downstream
signaling and glucose uptake. Of physiologic significance, deletion of hepatic ApoJ or muscle
LRP2 causes insulin resistance and glucose intolerance. In patients with polycystic ovary
syndrome and insulin resistance, pioglitazone-induced improvement of insulin action is
associated with an increase in muscle ApoJ and LRP2 expression. Thus, the ApoJ-LRP2 axis is
a novel endocrine circuit that is central to the maintenance of normal glucose homeostasis
and insulin sensitivity.
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Many metabolic organs mediate various aspects of inter-organ communication through secreted factors,including leptin1, interleukin-62, FGF213, adiponectin4,
selenoprotein P5, and ghrelin6. Among these molecules, liver-
derived proteins, such as FGF21 and selenoprotein P, now known
as hepatokines, can directly affect glucose and lipid metabolism in
adipose tissue, liver, or muscle7. The identification of hepatokines
has greatly advanced the field of metabolic physiology3,7. Over the
past decade, researchers have put forth intensive efforts to iden-
tify critical mediators in the muscle that control glucose meta-
bolism and insulin sensitivity8,9. However, it is unclear how
peripheral tissue-derived circulating metabolic signals regulate
insulin-mediated muscle metabolism.
Insulin resistance is a major risk factor for developing type 2
diabetes10,11, and is associated with plasma lipid and lipoprotein
abnormalities, including reduced HDL cholesterol and elevated
triglyceride levels with increased hepatic secretion of triglyceride-
rich VLDL12. In addition to these risk factors, various apolipo-
proteins particles, such as ApoCIII have gained increasing
attention as new indicators for type 2 diabetes13. Apolipoprotein J
(ApoJ, also called clusterin) was first described as a secreted
sulfated glycoprotein that is ubiquitously found in metabolic
tissues and body fluids14. ApoJ exists as multiple protein isoforms
including the 75–80 kDa highly glycosylated secreted form, and
the smaller intracellular forms that are not well characterized15,16.
The secretory isoform of ApoJ is thought to have molecular
chaperone activity depending on the degree of glycosylation17,18
and binds to specific cell surface receptors in mediating its bio-
logical effects, such as endocytosis19,20. Although the exact role of
ApoJ in many conditions remains unclear15, ApoJ has been
implicated in altered pathophysiologic disorders, including
atherosclerosis21, obesity22, diabetes23, and Alzheimer’s disease24.
ApoJ is found in plasma HDL and LDL, though its functions in
lipoprotein metabolism are unclear, while nuclear-localized and
cytoplasmic isoforms of ApoJ have been described, each with
distinct functions25. Interestingly, a recent study reported that the
serum ApoJ level closely correlates with insulin resistance and
decreases according to improvement of insulin sensitivity in
humans with type 2 diabetes26, suggesting a functional link between
ApoJ and insulin action. This is further supported by the findings
that ApoJ in HDL is correlated with insulin sensitivity but ApoJ in
LDL/VLDL is associated with insulin resistance27. However, a lack
of knowledge of how ApoJ links with the metabolic actions of
insulin in skeletal muscle has been a limitation in the field.
Low-density lipoprotein receptor-related protein-2 (LRP2, also
called gp330/megalin) is a member of the LDL receptor family of
lipoprotein receptors that bind to their extracellular ligands, such as
ApoE and ApoJ before endocytotic uptake19,20. LRP2 also binds to
leptin and mediates leptin transport crossing the choroid plexus28.
In addition, LRP2 interacts with selenoprotein P and promotes its
uptake in the proximal renal tubules of the kidney29. Although
LRP2 has not been suspected to participate in obesity, a study with
whole-exome sequencing analysis suggests that LRP2 could play a
role in the development of early-onset obesity30. While important
roles of LRP2 have been reported, nothing is known about the
metabolic action of LRP2 on muscle glucose metabolism.
In this study, we investigate the physiological roles of ApoJ and
LRP2 in insulin-dependent metabolic responses, with particular
focus on sources and tissue targets of ApoJ in the context of
interorgan crosstalk. Here, we identify the ApoJ → LRP2 axis
coupled with the IR system as a key endocrine circuit regulating
glucose homeostasis and insulin sensitivity.
Results
Liver is a major source of circulating ApoJ. To determine tissue
targets and/or sources of ApoJ, we generated mice lacking ApoJ in
liver (liver-specific ApoJ-deficient mice (L-ApoJ−/−)) by mating
ApoJ-floxed mice with albumin-Cre transgenic mice. A lack of
serum ApoJ was found in L-ApoJ−/− mice (Fig. 1a), suggesting
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Fig. 1 ApoJ levels in serum and multiple organs of L-ApoJ−/− mice. a ApoJ protein levels in serum of liver-specific ApoJ-deficient mice (L-ApoJ−/−).
Serum was separated by SDS–PAGE. ApoJ or ApoB 48 was visualized by immunoblotting. These data are representative from more than three independent
experiments. b ApoJ protein levels in multiple metabolic organs of L-ApoJ−/−. Tissue lysates (20–50 μg) were separated by SDS–PAGE. ApoJ or actin was
visualized by immunoblotting. These data are representative from more than three independent experiments. Mus muscle, Adi adipose tissue, Hypo
hypothalamus, Panc pancreas, Kid kidney, Stom stomach, Intes intestine, Spl spleen, BAT brown adipose tissue; C: ApoJloxP/loxP mice, KO: albumin-Cre:
ApoJloxP/loxP mice (L-ApoJ−/−). c mRNA levels of ApoJ in multiple metabolic organs of L-ApoJ−/− mice. mRNA levels of ApoJ were measured by RT-PCR.
Mice were studied at 12 weeks of age. Molecular marker (MM) is 100 bp DNA ladder. 313 bp indicates ApoJ mRNA. These data are representative from
three independent experiments; Con: ApoJloxP/loxP mice, KO: albumin-Cre: ApoJloxP/loxP mice (L-ApoJ−/−).
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that the liver is the major source of circulating ApoJ. In addition,
levels of ApoJ were very low or absent in numerous metabolic
organs of L-ApoJ−/− mice (Fig. 1b), which were not due to
altered gene expression of ApoJ (Fig. 1c). Collectively, these data
lead to the observation that ApoJ released by the liver into the
circulation has access to multiple metabolic tissues, where ApoJ
could play a role in the regulation of cellular metabolic events.
Liver-derived ApoJ can transport into multiple metabolic
organs. To test the hypothesis that liver-derived ApoJ can be
transported to metabolically active organs, an adenovirus carrying
secretory ApoJ was administered to L-ApoJ−/− mice via the tail
vein. Circulating ApoJ levels in L-ApoJ−/− mice injected with
adenovirus ApoJ were greatly elevated compared with the mice
injected with a control virus expressing green fluorescent protein
(GFP; Fig. 2a). Consistently, increased ApoJ content was seen in
multiple metabolic organs of L-ApoJ−/− mice injected with the
adenovirus expressing ApoJ (Fig. 2b). These data were further
confirmed with global ApoJ-deficient mice (ApoJ−/−; Fig. 2c, d).
Together, our results clearly demonstrate that liver-derived ApoJ
can accumulate in metabolically active tissues, raising the possibility
that hepatic ApoJ plays a key role in interorgan communication.
Circulating ApoJ is normal in mice lacking ApoJ in muscle. To
further test the hypothesis that ApoJ protein in muscle is pre-
served in mice, where ApoJ was deleted in muscle, due to ApoJ
produced by the liver, muscle-specific ApoJ-deficient mice (M-
ApoJ−/−) were studied. We found that serum ApoJ levels did not
differ between control and M-ApoJ−/− mice, indicating that
muscle ApoJ is not a major source of circulating ApoJ (Fig. 3a).
Importantly, M-ApoJ−/− mice had normal content of ApoJ
protein in muscle and other metabolic organs (Fig. 3b). ApoJ
mRNA was absent in muscle, whereas ApoJ mRNA was intact in
the other organs (Fig. 3c). Our current results, combined with the
results from L-ApoJ−/− mice injected with ApoJ adenovirus,
suggest that ApoJ in muscle comes from circulating ApoJ pro-
duced by the liver, and the relative contribution of muscle ApoJ to
total circulating ApoJ levels is quite limited. Rather, liver-derived
ApoJ would represent the major source of ApoJ in muscle.
L-ApoJ−/− mice display insulin resistance by impairing
insulin signaling. To determine the physiological function(s) of
liver-derived ApoJ, we characterized the metabolic phenotypes of
L-ApoJ−/− mice fed a normal chow diet. No significant differ-
ences emerged in body weight, fat mass, O2 consumption, and
CO2 production between control and L-ApoJ−/− mice (Fig. 4a,
Supplementary Fig. 2a–c). Blood glucose levels in the fasting
state were significantly increased, but insulin levels were normal
in L-ApoJ−/− mice compared with control mice (Fig. 4b, c). L-
ApoJ−/− mice had normal circulating levels of IGF-1, IGFBP-3,
and selenoprotein P (Figs. 4d, f, Supplementary Fig. 2f), but
increased serum IGFBP-1 levels (Fig. 4e). Neither serum alanine
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Fig. 2 Liver is a major source of circulating ApoJ. a ApoJ protein levels in serum of L-ApoJ−/− mice injected with ApoJ or GFP adenovirus. L-ApoJ−/− or
global ApoJ−/− mice were injected with a recombinant adenovirus encoding a secretory ApoJ or GFP at a concentration of 2 × 09 pfu per gram of body
weight via the tail vein. A: ApoJ-expressing adenovirus, G: GFP-expressing adenovirus. Serum was separated by SDS–PAGE. ApoJ, ApoB 48 or actin were
visualized by immunoblotting. b ApoJ protein levels in multiple metabolic organs of in L-ApoJ−/− mice injected with ApoJ or GFP adenovirus. Tissue
lysates (20–50 μg) were separated by SDS–PAGE. ApoJ or GAPDH were visualized by immunoblotting. c ApoJ protein levels in serum of in global ApoJ−/−
mice injected with ApoJ or GFP adenovirus. d ApoJ protein levels in multiple metabolic organs of global ApoJ−/− mice. Tissue lysates (20–50 μg) were
separated by SDS–PAGE. All data are representative from three independent experiments. Mice were studied at 9–10 weeks of age. Hypo hypothalamus,
BAT brown adipose tissue.
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aminotransferase (ALT), aspartate aminotransferase (AST), TG,
nor cholesterol levels were altered in L-ApoJ−/− mice (Supple-
mentary Fig. 2d, e, Fig. 4g–h). The contents of hepatic trigly-
ceride and cholesterol were not different between control and
L-ApoJ−/− mice (Fig. 4i–j). These data were confirmed by H&E
staining of the liver (Fig. 4k). In addition, deletion of hepatic
ApoJ had no effects on hepatic VLDL production and seleno-
protein P levels, as well as hepatic gene expression of key
enzymes involved in lipogenesis, gluconeogenesis, and glycolysis
(Fig. 4l, Supplementary Fig. 2g–h). Interestingly, muscle LRP2
mRNA level was increased in L-ApoJ−/− mice compared with
control mice (Supplementary Fig. 2i). This could be a compen-
satory effect, due to lack of its ligand.
Interestingly, selective deletion of hepatic ApoJ resulted in
insulin resistance in the fasting state, as indicated by the fasting
hyperglycemia, as well as failure to normalize glucose levels in the
presence of elevated insulin levels. Such resistance was indepen-
dent of adiposity (Fig. 4m). Of note, the slopes of the insulin
tolerance test (ITT) curves are similar between control and L-
ApoJ−/− mice (Fig. 4m), suggesting possible normal insulin
sensitivity. However, L-ApoJ−/− mice still have reduced insulin
responsiveness as maximal dose of insulin impairs insulin-
stimulated glucose uptake and signaling. L-ApoJ−/− mice also
displayed impaired glucose tolerance (Fig. 4n), which could result
from impairment of glucose-stimulated insulin secretion (GSIS;
Fig. 4o). We further determined the mechanism underlying
hepatic ApoJ deficiency-induced insulin resistance by investigat-
ing insulin signaling in insulin-sensitive tissues. Interestingly,
insulin-stimulated IR phosphorylation was markedly reduced by
~50‒65% in muscle, adipose tissue, and liver in L-ApoJ−/− mice
compared with control mice (Fig. 4p–r, Supplementary Fig. 2j–l).
Subsequently, phosphorylation of downstream components of
insulin signaling in skeletal muscle and adipose tissue, including
IRS-1/2, Akt, AS160, and GSK3, was also impaired in L-ApoJ−/−
mice (Fig. 4p–r, Supplementary Fig. 2j–l). These data suggest that
insulin resistance caused by hepatic ApoJ deficiency is most likely
due to decreased insulin signaling in insulin-target tissues,
primarily at the level of IR (Fig. 4p–r).
We further determined whether high-fat feeding could
exacerbate the metabolic phenotype of L-ApoJ−/− mice. Similar
to the results of normal chow diet, however, high-fat feeding had
no effects on body weight, and body mass between control and L-
ApoJ−/− mice (Supplementary Fig. 3a, b). Blood glucose levels
were increased but serum insulin levels were normal in L-ApoJ−/−
mice (Supplementary Fig. 3c, d). L-ApoJ−/− mice were insulin
resistant and glucose intolerant, and displayed impaired insulin
signaling (Supplementary Fig. 3e–i). Together, these findings
demonstrate that hepatic ApoJ is involved in the regulation of
whole-body glucose homeostasis and insulin sensitivity in vivo,
and further suggest that a functional crosstalk exists between
liver-derived ApoJ and insulin signaling in multiple tissues.
LRP2 is a potential receptor of ApoJ in muscle. Given that
LRP2 is a potential receptor of ApoJ19, it could be hypothesized
that ApoJ levels would increase in serum and decrease in muscle
if muscle LRP2 was deleted. We confirmed that LRP2 mRNA
levels in muscle were significantly decreased (by ~80%) in
muscle-specific LRP2-deficient mice (M-LRP2−/−) compared
with control mice, while LRP2 mRNA levels in other metabolic
organs were normal (Supplementary Fig. 4b). The ability to detect
muscle LRP2 protein by western analysis is constrained by the
fact that its content is very low in muscle. However, using in situ
proximity ligation assay (PLA), a powerful technology for
detecting proteins with high specificity and sensitivity31, we were
able to observe LRP2 protein in muscle of control mice but not in
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Fig. 3 ApoJ levels are normal in serum and muscle of M-ApoJ−/− mice. a ApoJ protein levels in serum of muscle-specific ApoJ-deficient mice (M-ApoJ−/−).
Serum was separated by SDS–PAGE. ApoJ was visualized by immunoblotting. b ApoJ protein levels in multiple metabolic organs of M-ApoJ−/−. Tissue lysates
(20–50 μg) were separated by SDS–PAGE. ApoJ was visualized by immunoblotting. c mRNA levels of ApoJ in multiple metabolic organs of M-ApoJ−/− mice.
mRNA levels of ApoJ were measured by RT-PCR. Mice were studied at 8 weeks of age. Molecular marker (MM) is 100 bp DNA ladder. 313 bp indicates ApoJ
mRNA. All data are representative from three independent experiments. Con: ApoJloxP/loxP mice, KO: myogenin-Cre: ApoJloxP/loxP mice (M-ApoJ−/−).
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muscle of M-LRP2−/− mice (Supplementary Fig. 4e). In addition,
endogenous ApoJ interacts with LRP2 in muscle of control mice:
this effect was not detected in muscle of M-LRP2−/− mice
(Supplementary Fig. 4f). These findings were confirmed by in vi-
tro studies showing that exogeneous ApoJ treatment significantly
increased the interaction between ApoJ and LRP2 in C2C12
muscle cells, as evidenced by increases in the number of red spots
at the cell surface of the cells. However, no interaction of LRP2
with insulin was found (Supplementary Fig. 4g), suggesting a
specificity of ApoJ binding to LRP2.
Consistent with our hypothesis, serum ApoJ levels measured by
ELISA were elevated by ~18% in mice lacking LRP2 in muscle
(M-LRP2−/−) compared to control mice (Fig. 5a). Concurrently,
muscle ApoJ levels of M-LRP2−/− mice, determined by
immunoblotting analysis, were lower than that of control mice
(Fig. 5b). Normal levels of ApoJ were found in other metabolic
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organs of M-LRP2−/− mice (Fig. 5c). Our results demonstrate
that circulating ApoJ is retained in muscle via LRP2 and that
LRP2 signaling could play a role in the maintenance of ApoJ
homeostasis in circulation, at least in part.
Muscle LRP2 deficiency leads to insulin resistance resulting
from impaired insulin signaling. To determine the role of LRP2
in muscle in control of glucose metabolism, we characterized the
metabolic phenotypes of M-LRP2−/− mice fed a normal chow
diet. Muscle-specific deletion of LRP2 had no effect on body
weight or blood glucose levels (Fig. 5d, e). However, M-LRP2−/−
mice had a higher risk for insulin resistance, as revealed by higher
serum insulin levels in the fasting state (Fig. 5f). Correspondingly,
M-LRP2−/− mice displayed insulin resistance (Fig. 5g), as evi-
denced by a blunted decrease in blood glucose levels after insulin
injection over control mice. Glucose tolerance was also impaired
in M-LRP2−/− mice compared with control mice (Fig. 5h). GSIS
did not differ between control and M-LRP2−/− mice (Fig. 5i).
To explore the mechanism(s) by which deletion of muscle
LRP2 contributes to systemic insulin resistance, we measured the
ability of insulin to activate insulin signaling in insulin-sensitive
tissues of M-LRP2−/− mice. Consistent with the results from L-
ApoJ−/− mice, insulin-stimulated IR phosphorylation was
decreased by ~50% in skeletal muscle of M-LRP2−/− mice,
compared with control mice (Fig. 5j, Supplementary Fig. 4c).
However, insulin-induced IR phosphorylation in the liver and
adipose tissue of M-LRP2−/− mice was normal (Fig. 5j). In M-
LRP2−/− mice, insulin’s ability to increase IRS-1 and Akt
phosphorylation were also markedly impaired in muscle, but
unaltered in the liver and adipose tissue (Fig. 5j). These data
suggest that LRP2 signaling is necessary for the regulation of
insulin-mediated signaling in skeletal muscle and further provides
in vivo evidence that ApoJ signaling is functionally linked with
insulin signaling.
Insulin-stimulated glucose uptake is impaired in L-ApoJ−/−
and M-LRP2−/− mice. To determine whether hepatic ApoJ
deletion or muscle LRP2 deficiency leads to impaired insulin-
mediated glucose uptake, we measured in vivo glucose uptake in
muscle, liver, and adipose tissue.
Notably, insulin stimulation of glucose uptake was markedly
decreased by ~30%, ~35%, and ~20% in muscle, adipose tissue,
and brown adipose tissue in L-ApoJ−/− mice compared with
control mice, respectively (Fig. 6a). Similarly, deletion of muscle
LRP2 led to a ~23% reduction in insulin-induced glucose uptake
in muscle, but not in adipose tissue or brown adipose tissue
(Fig. 6b). Given that defective insulin-mediated glucose transport
in skeletal muscle is a major contributor to the pathogenesis of
insulin-resistant states32, it is likely that systemic insulin
resistance caused by hepatic ApoJ deficiency or muscle LRP2
deletion results primarily from decreased insulin-stimulated
glucose uptake in skeletal muscle. Collectively, our findings
highlight that hepatic ApoJ and muscle LRP2 are required for
optimal insulin-mediated glucose uptake in muscle and further
implicate ApoJ → LRP2 signaling is critical for maintaining
normal glucose homeostasis.
LRP2 is required for insulin-induced insulin receptor inter-
nalization. To determine the mechanism(s) by which LRP2 is
involved in the regulation of insulin-mediated glucose metabo-
lism, we measured IR internalization, Akt phosphorylation, and
glucose uptake in C2C12-myc-Glut4 cells, where LRP2 was
knocked down. We confirmed that LRP2 mRNA levels were
reduced by ~86% in LRP2 siRNA-transfected cells compared with
control siRNA-transfected cells (Supplementary Fig. 4d). IR
undergoes internalization upon ligand stimulation33. As expected,
insulin rapidly stimulated IR internalization with ~35–50%
reduction of the cell surface IR by 60 min (Fig. 7a); this effect was
abolished by LRP2 inhibition (Fig. 7b). Consistent with the results
in M-LRP2−/− mice, insulin-induced Akt phosphorylation, and
glucose uptake were markedly decreased in C2C12-myc-Glut4
cells when LRP2 expression was suppressed (Fig. 7c, d). These
data clearly demonstrate that LRP2 is required for insulin-
induced IR internalization, which is crucial in regulating down-
stream signaling and glucose uptake.
Given that LRP2 is an endocytic receptor19,20,22, we tested if
clathrin-mediated endocytosis is involved in the regulation of
insulin signaling. In response to insulin, FOXO1 nuclear export
(from nucleus to cytosol), an indicator of activation of the PI3K/
Akt signaling pathway34, was markedly increased in C2C12 muscle
cells (Fig. 7e). However, this response was completely blocked
when muscle cells were treated with chlorpromazine or
cytochalasin D, an inhibitor of clathrin-mediated endocytosis,
(Fig. 7e), indicating that endocytosis is an essential step for this
insulin-stimulated response.
Pioglitazone reduces circulating ApoJ levels but increases
muscle ApoJ and LRP2 in humans with insulin resistance. An
example of a relationship between elevated ApoJ levels and
insulin resistance is seen in the polycystic ovary syndrome
(PCOS). Women with PCOS display insulin resistance in both the
fasting (HOMA2-IR) and insulin-stimulated glucose disposal rate
(GDR) states compared to BMI-matched normal cycling control
subjects (Table 1). Of note, women with PCOS have elevated
(~35%) serum ApoJ levels over healthy controls (Fig. 8a). As
expected, pioglitazone treatment of the PCOS subjects improved
insulin action, evidenced by decreased HOMA2-IR and increased
GDR (Fig. 8b, c, Table 1). Along with this, circulating ApoJ levels
in these subjects were reduced and essentially normalized (Fig.
8d); placebo was without effect on either characteristic. Serum
Fig. 4 Loss of hepatic ApoJ leads to insulin resistance and glucose intolerance without obesity. a Body weight (n= 7 for control, n= 9 for L-ApoJ−/−),
b fasting blood glucose (n= 7 for control, n= 9 for L-ApoJ−/−), c fasting serum insulin (n= 8 per group), d serum IGF-1 (n= 10 for control, n= 9 for
L-ApoJ−/−), e serum IGFBP-1 (n= 10 for control, n= 9 for L-ApoJ−/−), f plasma IGFBP-3 (n= 11 for control, n= 12 for L-ApoJ−/−), g serum triglycerides
(n= 6 for control, n= 7 for L-ApoJ−/−), h serum cholesterol (n= 6 for control, n= 7 for L-ApoJ−/−), i liver triglycerides (n= 7 per group), j liver
cholesterol (n= 6 per group), k H&E-stained liver sections, l hepatic VDLD-TG production (n= 5 per group), m results of insulin tolerance test (ITT; n= 6
per group), n results of glucose tolerance test (GTT; n= 6 for control, n= 8 for L-ApoJ−/−), o glucose-stimulated insulin secretion test (GSIS; n= 3 for
control, n= 4 for L-ApoJ−/−), p muscle insulin signaling, q liver insulin signaling, and r adipose tissue insulin signaling (n= 7 per group) were measured in
control and L-ApoJ−/− mice. Serum parameters were measured from overnight fasted mice at 11–13 weeks of age. H&E-stained liver sections are
representative from three independent experiments. The scale bars represent 100 μm. ITT was performed at 21 weeks of age and GTT was performed at
13 weeks of age. GSIS was performed at 16–18 weeks of age. Insulin signaling was performed at 25–26 weeks of age; AUC area under the curve. Logarithmic
transformation was done for GTT. The AUC in GSIS was calculated by 30min. All bars and errors represent means ± SEM. p values by two-sided Student’s
t-test in b and e, and by repeated measures two-way ANOVA in m and n are indicated. p values for AUCs were evaluated by one-sided Student’s t-test for
m and n, and by Mann–Whitney U test for o based on the distribution of the data. *p < 0.05 vs control by repeated measures two-way ANOVA.
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ApoJ levels in healthy and PCOS subjects were positively corre-
lated with fasting insulin, free fatty acid, HOMA2-IR, and
HOMA-β (%), and negatively correlated with GDR (Fig. 8e).
However, there was no association between serum ApoJ levels
and age, BMI, HDL cholesterol, LDL cholesterol, triglycerides,
and adiponectin levels (Fig. 8e, Supplementary Fig. 5). While
skeletal muscle, ApoJ protein levels and LRP2 mRNA in PCOS
subjects at baseline were not different compared to normal
cycling subjects (Fig. 8f, g), pioglitazone treatment of PCOS
subjects increased ApoJ protein content, as well as mRNA for
LRP2 (Fig. 8h, i).
Discussion
A major challenge in the field of metabolic physiology has been to
understand the interorgan communication networks linked to
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muscle-specific LRP2-deficient mice (M-LRP2−/−). Serum ApoJ levels were measured by ELISA. ApoJ, or ApoB 48 were visualized by immunoblotting.
Scatter diagram shows densitometric quantitation of ApoJ protein from control and M-LRP2−/− mice (n= 7 per group). b ApoJ protein levels in muscle of
M-LRP2−/−. Muscle lysates (20 μg) were separated by SDS–PAGE. ApoJ or GAPDH was visualized by immunoblotting. Scatter diagram shows
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LRP2−/−. Tissue lysates (20–50 μg) were separated by SDS–PAGE. ApoJ was visualized by immunoblotting. d Body weight (n= 12 per group), e random
blood glucose (n= 10 per group), f serum insulin (n= 11 for control, n= 7 for M-LRP2−/−), g insulin tolerance test (ITT; n= 5 per group), h glucose
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measured in control and M-LRP2−/− mice. Serum and muscle ApoJ level, body weight, and random blood glucose were measured at 16 weeks of age.
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by one-sided Student’s t-test for g and h. p values for AUCs were evaluated by one-sided Student’s t-test for g and h. p values for interaction in g and h
were obtained by Greenhouse–Geisser correction. *p < 0.05 vs control by repeated measures two-way ANOVA.
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muscle glucose metabolism35,36. One critical factor for this
interorgan system is now identified as hepatokines from liver-
derived proteins, which play a pivotal role in regulating glucose
metabolism and insulin sensitivity in skeletal muscle3,7. Discovery
of an unidentified hepatokine that is involved in insulin control of
glucose metabolism in skeletal muscle is thus of particular
interest. Here, we show that ApoJ functions as a hepatokine
targeting insulin signaling and glucose metabolism in skeletal
muscle; this action is mediated via the LRP2 signaling cascade.
We propose a model for the involvement of the ApoJ →
LRP2 signaling pathway in the maintenance of normal insulin
signaling and glucose homeostasis.
We investigated the role of ApoJ in the regulation of glucose
homeostasis and insulin signaling. Strikingly, our studies with
animal models, including L-ApoJ−/− mice, global ApoJ−/− mice,
and M-ApoJ−/− mice, demonstrated that the liver is a major source
of circulating ApoJ and that liver-derived ApoJ appears in meta-
bolically active organs, such as muscle, suggesting that ApoJ likely
plays a role in interorgan communication networks. The fact that
hepatic ApoJ deletion leads to impaired insulin action on muscle
glucose uptake without any changes in body weight further suggests
direct actions of liver-released ApoJ on insulin-dependent glucose
metabolism. Given that LRP2 is found to be a potential receptor for
ApoJ20,22,37, it is conceivable that ApoJ released by the liver effects
the action of insulin on glucose disposal in skeletal muscle via LRP2.
Consistent with this, experimental evidence revealed that insulin’s
ability to stimulate glucose uptake is decreased in the absence of
muscle LRP2. Thus, these findings suggest that ApoJ acts as a
hepatokine that plays a pivotal role in modulating muscle glucose
metabolism through LRP2, highlighting an interorgan commu-
nication network between liver and muscle.
The mechanisms for the involvement of LRP2 in the metabolic
actions of insulin remain unknown to date. Here, we show that
insulin receptors on the cell surface of muscle cells failed to
internalize in response to insulin when LRP2 expression was
suppressed, suggesting that LRP2 is required for insulin-induced
insulin receptor internalization, an early step in insulin signal-
ing38. Correspondingly, phosphorylation of downstream signal-
ing components for insulin, including IRS-1 and Akt, were greatly
reduced in muscle of M-LRP2−/− mice. As a result, glucose
uptake stimulated by insulin was decreased, ultimately leading to
insulin resistance. Therefore, it seems likely that the cellular
mechanism underlying insulin resistance induced by LRP2 dele-
tion involves a major defect in the internalization of insulin
receptor at the cell surface of muscle. Given that ApoJ is a ligand
for LRP220,22,37, a similar mechanism for insulin resistance
caused by a lack of circulating ApoJ was also detected, i.e.,
insulin’s ability to activate insulin receptor was impaired in
muscle of L-ApoJ−/− mice. However, we cannot rule out the
possibility that ApoJ/LRP2-mediated insulin action could be
independent of insulin receptor. Because LRP2 has NPXY motifs
in the cytoplasmic tail39, which are recognized by proteins con-
taining a phosphotyrosine-binding domain, such as IRS40,41, it is
thus possible that ApoJ/LRP2 modulates PI3K signaling via an
NPXY domain in a way that is independent of the insulin
receptor. Indeed, ApoJ activates survival through the PI3K/Akt
signaling pathway42.
Interestingly, the current study found that while L-ApoJ−/−
mice have no circulating ApoJ, M-LRP2−/− mice show a high
level of circulating ApoJ, yet both are insulin resistant. These
observations seem to be contradictory. However, a possible
explanation for this is that defective insulin signaling in skeletal
muscle of L-ApoJ−/− mice is likely due to impaired
LRP2 signaling caused by a lack of its ligand ApoJ, which
ultimately inhibits insulin action on glucose uptake. On the
other hands, in M-LRP2−/− mice, circulating ApoJ could not
act in muscle because of a lack of its cell surface receptor,
thereby impairing insulin’s ability to activate signaling. Under
this condition, circulating ApoJ would remain high, as it cannot
be utilized by muscle. In this regard, several studies show that
elevated circulating ApoJ level is associated with insulin resis-
tance in diet-induced obese mice43, as well as humans with
PCOS, type 2 diabetes, and atherosclerotic diseases23,26. How-
ever, insulin-sensitizing interventions, including exercise
training44,45 and pioglitazone treatment46, lead to a significant
decrease in circulating ApoJ in insulin-resistant humans. Thus,
it is plausible that a certain level of ApoJ in the circulation may
important in maintaining normal glucose homeostasis and
insulin sensitivity. If beyond a certain threshold or a lack of
ApoJ, ApoJ could desensitize insulin action on glucose meta-
bolism. Together, we suggest that ApoJ signaling plays a key
role as a co-factor in coordinating insulin-mediated signaling
events, i.e., if ApoJ signaling is functionally absent, insulin
signaling is affected correspondingly. Conversely, ApoJ signal-
ing could be augmented if insulin signaling is improved, as in
the cases of insulin-sensitizer treatment and exercise
training44,46. Additional differences between L-ApoJ−/− and
M-LRP2−/− mice include the fasting hyperglycemia and
impaired GSIS seen in the former animals, suggesting a role for
ApoJ in regulating ß-cell function that is retained in the pre-
sence of normal-to-elevated circulating ApoJ levels in the M-
LRP2−/− mice. ApoJ regulation of insulin secretion represents a
fertile topic for further study.
In this study, we further characterized the functional role of
hepatic ApoJ in the regulation of hepatic lipid metabolism. We
show herein that loss of hepatic ApoJ has no effects on hepatic
lipid metabolism, including VLDL-TG production and hepatic
lipid accumulation, indicating that metabolic dysfunctions caused
by hepatic ApoJ deficiency is not likely due to changes in hepatic
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brown adipose tissue (BAT) was measured in control and L-ApoJ−/− mice
(muscle: n= 20 per group, adipose tissue: n= 16 per group, BAT: n= 20
for control, n= 19 for L-ApoJ−/−). Mice were studied at 18 weeks of age.
b Insulin-stimulated glucose uptake in muscle, adipose tissue, and BAT was
measured in control M-LRP2−/− mice (muscle: n= 10 for control, n= 8 for
M-LRP2−/−, adipose tissue: n= 10 for control, n= 7 for M-LRP2−/−, BAT:
n= 10 for control, n= 8 for M-LRP2−/−). Mice were studied at 17 weeks of
age. Mice were injected with insulin in combination with [14C]2-
deoxyglucose. In vivo 2-deoxyglucose uptake was measured. All bars and
errors represent means ± SEM. p values by two-sided Student’s t-test in
a and b are indicated.
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lipid metabolism. Moreover, in PCOS subjects, changes in muscle
ApoJ by the insulin-sensitizer pioglitazone were observed in the
absence of any alterations in lipoprotein levels. However, ApoJ is
found to negatively regulate gene expression of SREBP1c, a
master regulator of the lipogenic pathways, leading to reductions
in hepatic lipid accumulation in HepG2 cells and diet-induced
obese mice47. Similarly, liver-specific overexpression of ApoJ
prevents the development of diet-induced hepatic steatosis48,
suggesting a sufficiency of hepatic ApoJ in modulating hepatic
lipid metabolism. Other studies revealed that treatment of HepG2
cells with recombinant ApoJ protein increased gene expression of
key molecules involved in gluconeogenesis49. Thus, the impor-
tance of hepatic ApoJ in hepatic lipid metabolism will require
further investigations.
Of note, a recent study demonstrated that ApoJ is secreted
from human adipocytes in vitro and its production is increased in
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response to palmitate49. However, a lack of detailed experimental
conditions is found in this report, even no information of ApoJ
antibody is provided. The composition of the media for adipocyte
culture is critical, because the level of ApoJ protein in serum is
used for culture is very high50,51, which could possibly effect the
outcomes of these experiments. For example, it is possible that
ApoJ in the media could be taken up by adipocytes, and then
released from the adipocytes into the media in response to sti-
muli. This study only measured ApoJ level in the media but not
adipocyte. Nevertheless, this observation should be confirmed in
the context of in vivo milieu. From our studies with L-ApoJ−/−
mice and global ApoJ−/− mice injected with an adenovirus
encoding a secretory form of ApoJ, it is likely that ApoJ in adi-
pose tissue could be that produced by the liver, as is the case with
muscle ApoJ. However, this supposition would need to be con-
firmed by studying adipose-specific ApoJ−/− mice.
On the basis of our findings, we propose a key mechanism for
involvement of ApoJ and LRP2 signaling in the metabolic action
of insulin on glucose metabolism (Fig. 9); circulating ApoJ is
secreted by the liver to enhance insulin-dependent muscle glucose
uptake. Liver-derived ApoJ is delivered to skeletal muscle where it
binds to its receptor LRP2 on the cell surface. ApoJ binding to
LRP2 is a unique mechanism to amplify insulin action by spe-
cifically driving IR internalization. Thus, our study identifies ApoJ
as a hepatokine that targets muscle LRP2 signaling, which plays a
key role in regulation of glucose homeostasis and insulin
signaling. This ApoJ → LRP2 signaling axis can be added to the
current networks of peripheral tissue-derived signals that serve as
autocrine or paracrine signals in the regulation of whole-body
fuel metabolism7,8,52.
Methods
Animal care. Animal studies were conducted in accordance with the National
Institutes of Health “Guide for the Care and Use of Laboratory Animals” (NIH
Publication No. 85-23, revised 1996) and approved by the Institutional Animal
Care and Use Committees of Beth Israel Deaconess Medical Center. The mice were
fed standard chow (Teklad F6 Rodent Diet 8664, Harlan Teklad, Indianapolis, IN)
or a high-fat diet (HFD) with 58% kcal in fat (D12331, Research Diets, New
Brunswick, NJ), and housed under controlled temperature at 22‒24 °C and a 12 h
light/12 h dark cycle with a humidity between 40–60%.
Experimental animals. Animals bearing a LoxP-flanked ApoJ allele (ApoJloxP/loxP
mice) were generated by inGenious Targeting Laboratory (Stony Brook, NY).
Briefly, a BAC clone (C57BL/6, RPC123 clone) containing a 9.32 kb fragment of
ApoJ genomic DNA was used to generate a targeting vector. Four independent
ApoJloxP/+ ES clones were identified, which were injected into C57BL/6 blastocysts
to generate chimeric mice. The chimeric mice were bred with wild-type C57BL/6
mice for germline transmission. Heterozygous animals were then crossed with mice
expressing flp-recombinase in the germline (Flipper mice, from The Jackson
Laboratory, Bar Harbor, ME) to delete the FRT-flanked Neo cassette. Offspring of
these mice were heterozygous for the desired ApoJloxP/+ allele. Albumin-Cre;
ApoJloxP/loxP mice (L-ApoJ−/−) and myogenin-Cre; ApoJloxP/loxP (M-ApoJ−/−)
were generated by mating ApoJloxP/loxP mice with albumin-Cre or myogenin-Cre
transgenic mice, respectively. For generation of M-LRP2−/− mice, LRP2loxP/loxP
mice53 were crossed with myogenin-Cre transgenic mice. Genotypes of these mice
were identified by polymerase chain reaction (PCR) or immunoblotting.
Table 1 Clinical and metabolic characteristics of normal cycle and PCOS women.
Normal cycle
(n= 7)
PCOS-placebo (n= 9) PCOS-pioglitazone (n= 11)
Pretreatment Posttreatment Change from
pretreatment
Pretreatment Posttreatment Change from
pretreatment
Age, years 33.4 ± 2.3 27.5 ± 0.9* – – 27.5 ± 1.3* – –
BMI, Kg/m2 35.3 ± 2.5 34.8 ± 2.2 36.7 ± 2.4 1.9 ± 1.2 38.2 ± 1.8 38.9 ± 2.0† 0.7 ± 0.6‡
Fasting glucose, mg/dL 99.3 ± 2.6 91.9 ± 1.3* 92.0 ± 2.2 0.2 ± 2.4 96.1 ± 3.2 89.6 ± 2.1 −6.5 ± 2.9
Fasting insulin, IU/L 14.3 ± 2.4 26.6 ± 2.7** 27.7 ± 3.0 1.3 ± 1.6 36.3 ± 4.7** 24.2 ± 4.2 −12.2 ± 3.7‡
HOMA2-IR 1.9 ± 0.3 3.1 ± 0.3* 3.5 ± 0.5 0.3 ± 0.3 4.4 ± 0.5** 2.8 ± 0.5 −1.6 ± 0.3#
HOMA-β, % 116.4 ± 10.8 203.4 ± 16.1** 210.0 ± 16.5 6.6 ± 12.5 240.4 ± 19.9** 190.5 ± 17.6 −49.9 ± 22.9
GDR, mg/kg/min 8.6 ± 0.7 7.1 ± 1.0 6.6 ± 0.9 −0.5 ± 0.5 5.3 ± 0.5** 6.5 ± 0.3 1.2 ± 0.3#
LDL cholesterol,
mg/dL
107.7 ± 16.9 116.4 ± 6.7 113.0 ± 10.2 −3.4 ± 6.2 109.4 ± 6.9 110.9 ± 8.0 1.4 ± 8.5
HDL cholesterol,
mg/dL
40.5 ± 1.9 44.8 ± 3.5 39.0 ± 2.2 −5.8 ± 4.1 39.2 ± 2.9 41.7 ± 2.9 2.5 ± 3.0
Triglyceride, mg/dL 122.2 ± 16.8 102.1 ± 13.6 81.0 ± 11.6 −21.1 ± 14.2 148.0 ± 13.9§ 126.7 ± 21.2 −21.3 ± 20.0
FFA, mmol/L – 1.17 ± 0.11 1.06 ± 0.09 −0.11 ± 0.19 1.15 ± 0.07 1.05 ± 0.10 −0.10 ± 0.08
Adiponectin, µg/mL 17.7 ± 1.9 9.6 ± 1.5** 11.4 ± 1.9 1.7 ± 2.7 9.1 ± 1.4** 19.2 ± 2.3 10.1 ± 1.8#
Data are expressed as frequency and means ± SEM. Comparison between groups was performed using ANOVA with a post hoc Fisher’s PLSD test and paired Student’s t-test.
BMI, body mass index; HOMA-IR, homeostasis model assessment-insulin resistance; HOMA-β (%), homeostasis model assessment-β (%); GDR, glucose disposal rate; FFA, free fatty acid.
*p < 0.05 vs normal cycle; **p < 0.01 vs normal cycle; §p < 0.05 vs PCOS-placebo; †p < 0.05 vs pretreatment; ‡p < 0.05 vs change from pretreatment of PCOS-placebo; #p < 0.01 vs change from
pretreatment PCOS-placebo.
Fig. 7 Inhibition of LRP2 impairs insulin receptor internalization in C2C12 muscle cells. a Time course of IR internalization following insulin binding in
C2C12 muscle cells. Cells were serum starved for 4 h and incubated with insulin as indicated, followed by sulfo-NHS-Biotin treatment. The biotinylated
surface protein fraction was pull-downed (PD) with streptavidin-agarose beads. Immunoblot indicates total IR in biotin-labeled cell surface (top) and total
lysates (bottom). Line graph shows the quantification of the relative cell surface IR amount at different time points by insulin treatment. These data are
representative from two independent experiments. b IR internalization following insulin binding in C2C12 muscle cells lacking LRP2. Cells were transiently
transfected by siRNA. Cells were starved for 4 h and incubated with insulin for 15min, followed by sulfo-NHS-Biotin treatment. The biotinylated surface
protein fraction was PD by streptavidin-agarose beads. Immunoblot indicates total IR in biotin-labeled cell surface (top) and total lysates (bottom). Bar graph
shows the quantification of the relative cell surface IR amount in cell surface IR and internalized IR. These data are representative from two independent
experiments. c Insulin-stimulated Akt phosphorylation in C2C12 muscle cells lacking LRP2. Cells were transiently transfected by siRNA. Cells were starved for
4 h and incubated with insulin for 15min. Total cell lysates were separated by SDS–PAGE. Akt was visualized by immunoblotting. Graph shows the
quantification of insulin-stimulated Akt phosphorylation from three independent experiments. d Insulin-stimulated glucose uptake in in C2C12 muscle cells
lacking LRP2. Cells were transiently transfected by LRP2 siRNA. Cells were starved for 3 h and incubated with insulin for 30min; n= 4 for control (no
insulin), n= 6 control (insulin), n= 6 for LRP2 siRNA (no insulin), n= 5 for LRP2 siRNA (insulin). [3H]-2-deoxy-D-glucose uptake was measured. All bars
and errors represent means ± SEM. p values by one-way ANOVA followed by post hoc Tukey’s HSD test are indicated. e Insulin-induced subcellular
localization of FOXO1 in C2C12 cells. C2C12 muscle cells were treated with or without insulin in the presence of chlorpromazine or cytochalasin D. FOXO1 was
detected by immunofluorescent analysis. These data are representative form three independent experiments. The scale bars represent 10 μm.
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Myogenin-Cre transgenic mice were generously provided by Dr. Zoltan Arany
(University of Pennsylvania, Philadelphia, PA). Albumin-Cre transgenic mice and
global ApoJ−/− mice were purchased from The Jackson Laboratory (Bar Harbor,
Maine).
Adenovirus-mediated gene transfer. ApoJloxP/loxP and L-ApoJ−/− mice were
injected with a recombinant adenovirus encoding a secretory ApoJ at a con-
centration of 2 × 109 plaque-performing units (pfu) per gram of body weight via
the tail vein. As a control, adenovirus encoding GFP was also injected. Blood
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Fig. 8 Serum ApoJ is elevated in insulin-resistant subjects with PCOS and normalized by pioglitazone, an insulin-sensitizing drug. a Serum ApoJ levels
in normal cycling (normal) and PCOS subjects. Immunoblots represent serum ApoJ and Apo B48 protein in normal and PCOS subjects. Ponceau S staining
indicates that equal amounts of protein in each lane was loaded on the gel. Scatter diagram shows serum ApoJ levels measured by ELISA from normal (n=
5) and PCOS subjects (n= 19). b Changes in HOMA2-IR after placebo (n= 8) or pioglitazone treatment (n= 10) in PCOS subjects. c Changes in glucose
disposal rate after placebo (n= 8) or pioglitazone (n= 9) treatment in PCOS subjects. d Changes in serum ApoJ levels after placebo (n= 7) or
pioglitazone treatment (n= 10) in PCOS subjects. All bars and errors represent means ± SEM. e Relationship of serum ApoJ with fasting insulin levels (n=
38), HOMA2-IR (n= 38), HOMA-β (%) (n= 38), GDR (n= 40), HDL cholesterol (n= 31), LDL cholesterol (n= 31), free fatty acid (n= 31), and
adiponectin (n= 40) levels in normal and PCOS subjects. p values were obtained by Spearman’s rank correlation analysis and r values indicate Spearman’s
correlation coefficient. f Muscle ApoJ levels in normal (n= 8) and PCOS subjects (n= 21). PCOS subjects were treated with placebo or pioglitazone.
g Muscle LRP2 levels in normal (n= 6) and PCOS subjects (n= 19). h Changes in muscle ApoJ levels after placebo (n= 6) or pioglitazone treatment (n=
12) in PCOS subjects. i Changes in muscle LRP2 levels after placebo (n= 6) or pioglitazone (n= 6) treatment in PCOS subjects. All bars and errors
represent means ± SEM. p values by two-sided Student’s t-test in a, c, d, h, and i are indicated.
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samples for analyzing serum ApoJ levels were drawn at 3‒5 day after the adeno-
virus injections. Mice were sacrificed in the fasted state at 5 days after the injec-
tions. Tissues were rapidly removed, snap-frozen in liquid nitrogen, and stored at
−80 °C until analysis.
Tissue lysates. Fifty milligrams of tissue were homogenized using a Tissue Lyser
(Qiagen, Valencia, CA) in a 500 μl buffer A (20 mM Tris pH 7.5, 5 mM EDTA,
10 mM Na4P2O7, 100 mM NaF, 2 mM Na3VO4) containing 1% NP-40, 1 mM
PMSF, 10 μg/mL aprotinin, and 10 μg/mL leupeptin. Tissue lysates were solubilized
by continuous stirring for 1 h at 4 °C, and centrifuged for 10 min at 14,000 × g. The
supernatants were stored at −80 °C until analysis.
RNA isolation and mRNA measurement. Total RNA was isolated by the Trizol
Reagent (Invitrogen, CA). Single strand cDNA from total RNA was synthesized by
reverse transcription (RT-PCR) kit (Clontech, Mountain View, CA) according to
the kit instruction. For ApoJ mRNA, PCR reaction was performed in a 20 μl
volume containing 10 ng of cDNA for 35 cycles. The forward primer 5ʹ-ACA ATG
GCA TGG TCC TGG GAG AG-3ʹ and the reverse primer 5ʹ-GTA TGC TTC AGG
CAG GGC TTG C-3ʹ were used. The PCR products were separated on 0.9%
agarose gels and analyzed with gel-imaging system (VersaDoc Multi Imaging
Analyzer System, Bio-Rad Laboratories, Hercules, CA).
Blood parameter measurements. Blood was collected either from random-fed or
overnight fasted mice via the tail. Blood glucose was measured using a OneTouch
Ultra glucose meter (LifeScan, Inc., Milpitas, CA). Serum insulin and leptin levels
were measured by ELISA (Crystal Chem, Chicago, IL). Serum total cholesterol and
triglyceride levels were determined by enzymatic methods (Stanbio Laboratory,
Boerne, TX). Serum IGF-1, serum IGFBP-1, plasma IGFBP-3, and serum ApoJ
levels were determined by ELISA (MG100, DY1588-05, MGB300, MCLU00, R&D
Systems, Minneapolis, MN). The range and sensitivity for these parameters are:
glucose, 40–500 mg/dL; leptin, 1–25.6 ng/mL (sensitivity, 200 pg/mL using a 5-μL
sample); insulin, 0.1–12.8 ng/mL (sensitivity, 0.1 ng/mL using a 5-μL sample); total
cholesterol, 1–750 mg/dL; triglyceride, 1–1000 mg/dL; IGF-1, 31.2–2000 pg/mL
(sensitivity, 8.4 pg/mL); IGFBP-1, 23.4–1500 pg/mL, IGFBP-3, 78.1–5000 pg/mL
(sensitivity, 16 pg/mL); and ApoJ, 0.781–50 ng/mL (sensitivity, 0.031 ng/mL).
Serum ALT and AST were measured by colorimetric assay kits (Cat# K752, Cat#
K753, Biovision, Milpitas, CA) according to manufacturer’s instruction. All assays
were performed blinded.
Body composition and energy expenditure. Mice were weighted from 4 weeks of
birth and weekly thereafter. Fat and lean body mass were assessed by EchoMRI
(Echo Medical Systems, Houston, TX). Energy expenditure was measured by
assessing oxygen consumption with indirect calorimetry. Individually housed male
mice maintained on a chow diet until 8 weeks of age were studied using the
Comprehensive Lab Animal Monitoring System (CLAMS, Columbus Instruments,
Columbus, OH). Mice were acclimated in the CLAMS chambers for 72 h before
data collection. Mice had free access to food and water for the duration of the
studies. During the course of the energy metabolism measurements (O2 and CO2)
using CLAMS, high variations (overlapping) in measurements emerged at indivi-
dual time points between groups. This did not allow us to statistically analyze
individual time points. To enhance the statistical power of these measurements, we
combined each value from the individual time points and analyzed the data by
unpaired Student’s t-tests to compare the two groups.
GTT and ITT. For glucose tolerance tests (GTT), male ApoJloxP/loxP mice and L-
ApoJ−/− mice at 13–14 weeks of age, or male LRP2loxP/loxP and M-LRP2−/− mice
at 18 weeks of age were fasted overnight, and blood glucose was measured before
and 15, 30, 60, 90, and 120 min after intraperitoneal injection of glucose (1.0 g/kg
of body weight). For insulin tolerance tests (ITT), male ApoJloxP/loxP mice and
L-ApoJ−/− mice at 19–21 weeks of age, or male LRP2loxP/loxP and M-LRP2−/−
mice at 24 weeks of age were fasted for 5 h, and blood glucose was measured before
and 15, 30, 60, 90, and 120 min after intraperitoneal injection of human insulin
(Humulin®, Lilly, Indianapolis, IN). A total of 0.5 unit/kg of body weight for mice
fed a chow diet and 0.75 unit/kg of body weight for mice fed a HFD were used.
Area under the curve for glucose or insulin was calculated54.
GSIS test. For glucose-stimulated insulin secretion (GSIS) test, male ApoJloxP/loxP
mice and L-ApoJ−/− mice at 16–18 weeks of age, or male LRP2loxP/loxP and
M-LRP2−/− mice at 22 weeks of age were fasted overnight, and serum insulin level
was measured before and 15, 30, and 60 min after intraperitoneal injection of
glucose (1.0 g/kg of body weight). Area under the curve for insulin was
calculated54.
In vivo hepatic VLDL-triglyceride production. Male ApoJloxP/loxP mice and
L-ApoJ−/− mice were injected with a 15% Tyloxapol solution in 0.9% NaCl
(600 mg/kg; Sigma-Aldrich, St. Louis, MO) intraperitoneally after an overnight fast
at 11 weeks of age. Triglyceride levels were measured before and 60, 120, 180, and
300 min after the injection.
Liver histology and lipid assay. The liver was fixed with 10% neutral buffered
formalin (F5554, Sigma-Aldrich), embedded in paraffin, and stained with H&E.
Liver lipids were extracted using chloroform/methanol (2:1) as a solvent. Total
cholesterol and triglyceride content of the liver were determined by an enzymatic
method (Cat#1010, Stanbio Laboratory; Cat #10010303, Cayman Chemical).
In vivo glucose uptake. Male mice at 17–18 weeks of age were studied. Twelve
hours fasted mice were injected with either saline or insulin (2 mU/g) in combi-
nation with 0.33 μCi [14C]2-deoxyglucose (2-DOG)/g and glucose (1 mg/g)
administered via the retro-orbital sinus under isoflurane anesthesia. Mice were
awake for the rest of procedure. Blood samples were taken 5, 10, and 15 min after
injection for the determination of glucose and [14C] levels to calculate the
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Fig. 9 A role of the ApoJ→ LRP2 signaling pathway in glucose homeostasis and insulin signaling. Circulating ApoJ is dominantly produced by the liver.
Liver-derived ApoJ then transports to skeletal muscle where it binds to its receptor LRP2 on the cell surface, leading to increased molecular interaction
between LRP2 and IR. The complexes of LRP2 with the IR then undergo co-endocytosis, which is an essential step of insulin signaling in skeletal muscle. As
a result, downstream signaling components activate, leading to enhanced glucose transport system activity. Thus, the ApoJ → LRP2 signaling pathway is
central in regulation of glucose homeostasis and insulin signaling.
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integrated glucose-specific activity area under the curve. At 15 min, mice were
sacrificed by decapitation and tissues rapidly collected and frozen in liquid nitro-
gen. Accumulation of [14C]2-deoxyglucose into skeletal muscle, adipose tissue, and
brown adipose tissue was measured using a perchloric acid and barium hydroxide/
zinc sulfate (Ba(OH)2/ZnSO4) precipitation procedure55. Tissues were weighed and
homogenized in 0.5% perchloric acid. Homogenates were centrifuged and super-
natants were neutralized with potassium hydroxide. One aliquot was counted
directly to determine 2-DOG and phosphorylated 2-DOG (2-DOG-P) radio-
activity. A second aliquot was treated with Ba(OH)2 and ZnSO4 to remove 2-DOG-
P, and then counted to determine 2-DOG radioactivity. Glucose uptake was cal-
culated from the difference between the radioactivity of these two aliquots divided
by the integrated glucose-specific activity area under the curve and normalized to
tissue weight.
Acute insulin stimulation. Male ApoJloxP/loxP and L-ApoJ−/− mice at 24–26 weeks
of age, or male LRP2loxP/loxP and M-LRP2−/− mice at 24 weeks of age were fasted
overnight. Mice were injected intraperitoneally with human insulin (10 U/kg of body
weight; Humulin®) or saline and scarified 10min later. Tissues were rapidly removed,
snap-frozen in liquid nitrogen, and stored at −80 °C until analysis.
Immunoblotting analysis. Tissue lysates (20–50 μg protein) or cell lysates (20 μg
protein) were resolved by sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS–PAGE) and transferred to nitrocellulose membranes (GE Health-
care Life Sciences, Pittsburgh, PA). The membranes were incubated with:
polyclonal antibodies against phosphor-Y972 IR (Cat#: 44-800 G); phosphor-Y612
IRS-1 (Cat#: 44-816 G; both Invitrogen; Carlsbad, CA); phospho-Ser473Akt (Cat#:
4060); phospho-Thr308Akt (Cat#: 4056); phospho-Thr642AS160 (Cat#: 4288);
phospho-Ser21/9 GSK3 (Cat#: 9331); phospho-Ser641 glycogen synthase (Cat#:
3891); phosphor-Ser240/244 S6 ribosomal protein (Cat#: 2215; all Cell Signaling
Technology, Beverly, MA); active MAPK (pTEpY) antibody (Cat#; V8031; Pro-
mega, Madison, WI); ApoJ/Clusterin (sc-8354); IR (sc-711); Akt (sc-7126);
GAPDH (sc-47724); selenoprotein P (sc-376858; all Santa Cruz Biotechnology,
Dallas, TX), or monoclonal antibodies against ß-actin (A2228, Sigma-Aldrich, St.
Louis, MO). Dilution of all antibodies was 1:1000 except active MAPK, which was
1:5000. The membranes were washed with Tris-buffered saline (TBS) containing
0.05% Tween 20 for 30 min, incubated with horseradish peroxidase secondary
antibodies (1:2000 dilution; GE Healthcare Life Sciences) for 1 h, and washed with
TBS containing 0.05% Tween 20 for 30 min. The bands were visualized with
enhanced chemiluminescence and quantified by an ImageJ program (v1.52a, NIH).
All phosphorylation data were normalized by total protein levels. Uncropped and
unprocessed scans of all blots are provided in the Source Data File.
Immunoprecipitation analysis. For IRS-2 phosphorylation, liver lysates (1 mg)
were subjected to immunoprecipitation with 5 μl of a polyclonal IRS-2 antibody (a
gift from Dr. Morris White, Children’s Hospital, Boston, MA) coupled with protein
A-Sepharose (Sigma-Aldrich). The immunoprecipitates were washed three times
with buffer A, and resuspended in a 4× Laemmli sample buffer, and heated for
5 min. The immunoprecipitates were resolved by SDS–PAGE and transferred to
nitrocellulose membranes. The membranes were incubated with a monoclonal
antibody against phosphotyrosine (PY 20; Santa Cruz Biotechnology). The bands
were visualized with enhanced chemiluminescence and quantified by an ImageJ
program.
In situ PLA. Male LRP2loxP/loxP and M-LRP2−/− mice at 18 weeks of age were
fasted overnight. Gastrocnemius muscles were harvested and fixed with formalin
overnight and embedded with paraffin. Muscle sections (5 μm) were boiled in 10
mM citrate buffer for antigen retrieval followed by blocking at 37 °C and then
incubated with primary antibody against LRP2 (Cat#; NB110-96417, Novus bio-
logicals, Littleton, CO) overnight. PLA was performed using the Duolink® In Situ
Detection Reagents Red with PLA probes Anti-PLUS and Anti-MINUS for mouse
(Sigma-Aldrich). The nuclei of cells were stained using Duolink® In Situ Mounting
Medium with DAPI (Sigma-Aldrich). Images were captured by a confocal
microscope (Zeiss LSM 880, Zeiss). For in vitro studies, C2C12-myc-GLUT4 cells
were incubated with 100 nM ApoJ (a gift from Dr. Min Bon Hong, Korea Uni-
versity, Seoul, Korea) or 100 nM insulin for 15 min. Cells were washed ice-cold PBS
three times and fixed with ice-cold methanol. Cells were incubated with primary
antibodies against ApoJ (Cat#; sc-8354, Santa Cruz Biotechnology) and LRP2
(Novus biologicals) overnight. PLA was performed using the Duolink® In Situ
Detection Reagents Red with Duolink® In Situ PLA probe Anti-rabbit PLUS and
Anti-mouse MINUS (Sigma-Aldrich). The nuclei of cells were stained using
Duolink® In Situ Mounting Medium with DAPI (Sigma-Aldrich). Images were
captured by a fluorescence microscope (Leica DMi8, Leica) and image data were
analyzed by AxioVision software (v 4.2 SP1, ZEISS).
Cell culture. C2C12 cells (ATCC, CRL-1772) were maintained in high glucose
DMEM (Thermo fisher scientific, Waltham, MA) supplemented with 10% FBS
(Thermo fisher scientific) and 1% Antibiotic-Antimycotic (Thermo fisher scientific).
C2C12-myc-GLUT4 cells (a gift from Dr. Amira Klip, The Hospital for Sick Children,
Toronto, Canada) were maintained in high glucose DMEM supplemented with 10%
FBS, 1% Antibiotic-Antimycotic and 100 μg/mL Blasticidin S HCL (Thermo fisher
scientific). Cell lines were tested monthly for mycoplasma contamination.
Transfection. C2C12-myc-GLUT4 cells were plated at a density of 1 × 105/well on
six-well plates on the day of transfection. Lipofectamine RNAiMax (Thermo fisher
scientific), 100 nM Lrp2 siRNA (s201412, Thermo fisher scientific), or scRNA
(negative control siRNA, AM4635, Thermo fisher scientific) was diluted in media,
respectively. The diluted siRNAs were added to the diluted Lipofectamine RNAi-
Max, and then incubated for 15 min at room temperature. The
siRNA–Lipofectamine complex was added to the cells. After transfection for 48 h,
the transfected cells were subjected to the isolation of total RNA or protein.
Insulin receptor internalization assay. The LRP2 siRNA- or scRNA-transfected
C2C12-myc-GLUT4 cells were serum starved for 4 h, followed by the stimulation
with 100 nM insulin for 0–30 min. The cells were rinsed with ice-cold PBS, fol-
lowed by 0.3 mg/mL sulfo-NHS-Biotin (Thermo fisher scientific) labeling at 4 °C
for 30 min. Then, the cells were quenched with ice-cold 100 mM glycine at 4 °C for
10 min. The cells were washed three times with ice-cold PBS, and then lysed with
NP40 Cell Lysis Buffer (Thermo fisher scientific) supplemented with Halt™ Pro-
tease and Phosphatase Inhibitor Cocktail (Thermo fisher scientific) and 1 mM
PMSF. The 100 μg total protein was incubated with 10 μl streptavidin-agarose
beads (50% slurry, Thermo fisher scientific) at 4 °C overnight to pull down the
biotinylated surface proteins. The beads were washed with lysis buffer three times,
and then boiled in SDS–PAGE loading buffer (NuPAGE™ LDS Sample Buffer
containing with NuPAGE™ Sample Reducing Agent (Thermo fisher scientific) at
100 °C for 10 min. The biotinylated surface protein fraction and the total protein
lysate were resolved on 4–16% Mini-PROTEAN TGXTM precast protein gels (Bio-
Rad, Hercules, California), transferred to nitrocellulose membrane, and immuno-
blotted using each antibody. The bands were visualized with enhanced chemilu-
minescence and quantified by an ImageJ program.
In vitro glucose uptake. C2C12-myc-GLUT4 cells were serum starved for 3 h in
serum-free DMEM (25 mM glucose) at 37 °C. and then washed once with glucose-
free minimum Eagle’s medium. Insulin (100 nM) or vehicle was added for 30 min,
followed by the addition of 100 μM [3H]-2-deoxy-D-glucose (PerkinElmer, Wal-
tham, MA), 0.33 μCi per 35-mm diameter well. Cells were incubated for a further
10 min at 37 °C. Transport was subsequently stopped by placing the cells on ice and
adding 1:1 (v/v) ice-cold phloretin solution (82 μg/liter in phosphate-buffered
saline; Sigma). Cells were washed once with cold PBS, solubilized in 1 N NaOH at
37 °C for 30 min, and [3H]2-deoxy-D-glucose incorporation was measured by
liquid scintillation counting. The results were was expressed as a percentage of
basal glucose transport in control cells.
Immunofluorescent analysis. C2C12 cells were treated with or without insulin
(10 nM) in the presence of chlorpromazine (30 μM) or cytochalasin D (2 μM). Cells
were then fixed in methanol, and rinsed with PBS. The fixed cells were incubated
overnight with a rabbit antibody to FOXO1 (ab70382, 1:50, Abcam, Cambridge,
MA) at 4 °C overnight. The primary antibody was washed and slides were incu-
bated for 1 h with an Alexa Fluor 488-conjugated antibody to rabbit IgG (Cat#; A-
11008, 1:500, Invitrogen, Carlsbad, CA). For counterstaining of nuclei, cells were
incubated with DAPI (Sigma-Aldrich). Images of green fluorescence were assessed
by a confocal microscope (Zeiss LSM 880, Zeiss).
Quantitative real-time PCR. Total RNA was extracted from each tissue or cell
using a TRIzol reagent (Invitrogen, CA) and subjected to quantitative real-time
PCR as described56. Single stranded cDNA from the total RNA was synthesized
with a RT-PCR kit (Clontech, Mountain View, CA) according to the kit’s
instructions. Quantitative RT-PCR was performed with an Applied Biosystems
7900HT Fast System using either a SYBR Green PCR Mastermix reagent (Applied
Biosystems, Foster City, CA) or TagMan® Gene Expression Assays (Applied Bio-
systems). Relative mRNA expression levels were determined using the 2−ΔΔCT
method normalized to 36B4. For LRP2 mRNA in human muscle, the forward
primer 5ʹ-CCA GCA AGG AAC CAG AGA ACA-3ʹ and the reverse primer 5ʹ-
AGG CAG AGC AAA GCA GAG ATG-3ʹ were used. For LRP2 mRNA in C2C12
cells, the forward primer 5ʹ-GAG TGC ATC CTT CGT GCC TAT-3ʹ and the
reverse primer 5ʹ-CAG CCA TCC TCA TCA CCA GAA-3ʹ were used. For LRP2
mRNA in mouse muscle, the commercial primers for LRP2 (Mm01328171_m) and
18 s (Mm0427787_s1) (Applied Biosystems) were used.
Clinical study. The current study is a post hoc analysis of samples collected from the
parent study under which subjects were recruited and treated which has been
described previously57,58. The experimental protocol and post hoc analysis were
approved by the Human Research Protection Program of the University of California,
San Diego and VASDHS IRB. Our studies were performed prior to ClinicalTrials.gov
identifier requirements. Twenty-eight PCOS and six non-PCOS subjects were
recruited between March 20, 2002 and January 6, 2006. Informed written consent was
obtained from all subjects after explanation of the protocol. We have complied with
all relevant ethical regulations regarding studies with human research participants.
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Briefly, subjects with PCOS were screened by medical history, physical examination,
and laboratory evaluation. The diagnosis of PCOS was based on criteria recom-
mended by the 1990 National Institutes of Health Conference on PCOS59. All par-
ticipants were pre-menopausal, and medication use was stable for at least 60 days
before screening. None of the subjects were diabetic or had a family history of type 2
diabetes. Other exclusion criteria included pregnancy; weight loss or gain >3 kg over
the last 3 months; a basal 17-OHP value of <3 ng/mL (9.1 nmol/L); or medication use,
including glucocorticoids, antiandrogens, ovulation induction agents, metformin, and
anti-obesity agents within 60 days prior to screening. All procedures were performed
in the early or mid-follicular phase (d 2–8) of the subjects’ menstrual cycle, except in
those subjects who did not have regular menses. Following pretreatment testing,
including glucose clamp and percutaneous needle biopsies of vastus lateralis muscle
before clamp steady-state insulin infusion, subjects with PCOS were given either
placebo or pioglitazone, 45 mg/d, for 6 months. At the end of the treatment period,
each subject underwent the same tests as in the pretreatment phase. All studies were
performed after a 12–14 h overnight fast. Blood was collected and serum isolated and
immediately stored at −80 °C. Insulin action in the fasting state was determined in all
subjects by calculating the HOMA2-IR60. All of the subjects had maximal insulin
action measured by a 3 h hyperinsulinemic (300mU/m2/min) euglycemic (5.0–5.5
mmol/L) glucose clamp; the GDR was measured during the last 30min of the clamp
steady-state period61. All of the prespecified primary outcomes of the parent study
have been reported previously (57) and there were no predefined secondary outcomes
in the study protocol. ApoJ levels were measured by ELISA kit (Boster biological
technology, Pleasanton, CA, USA; sensitivity= 20 pg/mL, interassay cv= 6.9–7.5%,
intraassay cv= 4.2–4.6%). Samples were diluted to be analyzed within range of the
standard curve (0.78–50 ng/mL). Some samples of ApoJ levels were also assessed by
immunoblotting analysis. Adiponectin levels were measured by radioimmunoassay kit
from Linco (St. Louis, MO; sensitivity= 2 μg/mL, interassay cv= 7%, intraassay cv=
11%). Free fatty acid levels were measured by colorimetric assay (Wako Chemicals,
Nuess, Germany). TG, HDL cholesterol, and LDL cholesterol were measured by
quantitative enzymatic assay at ARUP Laboratories (Salt Lake City, Utah).
Statistical analyses. Data are presented as means ± SEM and individual data
points are plotted. Sample size was determined by our experience with inherent
variability, especially with outbred strains. No statistical method was used to
predetermine sample size. The distribution of the data and homogeneity of var-
iances were analyzed by Shapiro–Wilk and Levene’s tests, respectively. Unpaired
Student’s t-tests were used throughout this study to compare two distinct groups if
the data were distributed normally, unless non-parametric Mann–Whitney U test
was used. When more than two groups were compared, one-way analysis of var-
iance (ANOVA) was performed with post hoc tests, Fisher’s PLSD and Tukey HSD
tests. Repeated measures two-way ANOVA was performed for GTT, ITT, and
GSIS. When intervention or interaction (intervention-by-time) was significant by
repeated measures two-way ANOVA, post hoc analyses were performed by pro-
viding extra codes into the SPSS program for multiple comparisons. The paired t-
test was used to compare pretreatment- and posttreatment. Statistical analyses were
performed using Stat View version 5.0 (Abacus Concepts, Berkeley, CA) and SPSS
version 18.0 for window (SPSS, Inc., Chicago, IL). Spearman’s rank correlation
analysis was used to assess the correlations between ApoJ levels and each covariate
was evaluated. All reported p values were two-sided unless otherwise described.
Differences were considered significant at p < 0.05.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that the data supporting the findings of this study are available
within the paper and its supplementary information files. Source data underlying
Figs. 4a–j, l–o, 5a, b, d–i, 6a, b, 7a–d, and 8a–i, and Supplementary Figs. 2a–l, 3a–h, 4b–d,
and 5 are provided as a Source Data File. The numerical data underlying Table 1 is
provided as a Source Data File.
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